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Summary
Charcot-Marie-Tooth disease (CMT) with deafness is
clinically distinct among the genetically heterogeneous
group of CMT disorders. Molecular studies in a large
family with autosomal dominant CMT and deafness
have not been reported. The present molecular study
involves a family with progressive features of CMT and
deafness, originally reported by Kousseff et al. Genetic
analysis of 70 individuals (31 affected, 28 unaffected,
and 11 spouses) revealed linkage to markers on chro-
mosome 17p11.2-p12, with a maximum LOD score of
9.01 for marker D17S1357 at a recombination fraction
of .03. Haplotype analysis placed the CMT-deafness lo-
cus between markers D17S839 and D17S122, a ∼0.6-
Mb interval. This critical region lies within the CMT
type 1A duplication region and excludesMYO15, a gene
coding an unconventional myosin that causes a form of
autosomal recessive deafness called DFNB3. Affected in-
dividuals from this family do not have the common 1.5-
Mb duplication of CMT type 1A. Direct sequencing of
the candidate peripheral myelin protein 22 (PMP22)
gene detected a unique GrC transversion in the hetero-
zygous state in all affected individuals, at position 248
in coding exon 3, predicted to result in an Ala67Pro
substitution in the second transmembrane domain of
PMP22.
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Introduction
Charcot-Marie-Tooth disease (CMT; MIM 118300)
(Charcot and Marie 1886; Tooth 1886) is comprised of
a clinically and genetically heterogeneous group of po-
lyneuropathies, with a prevalence of ∼1 in 2,500 (Skre
1974). It is characterized by degeneration of peripheral
nerves, resulting in distal muscle atrophy, sensory loss,
and deformities of the hands and feet. Two major dom-
inant clinical types have been defined on the basis of
electrophysiological studies (Lupski et al. 1991; Dyck et
al. 1992). CMT type 1 is characterized by uniformly
decreased nerve conduction velocities (!38 m/s) associ-
ated with nerve demyelination. CMT type 2 displays
normal to near-normal nerve conduction velocities (138
m/s), associated with a neuronal defect. The two auto-
somal dominant types of CMT type 1 are CMT type
1A and CMT type 1B. CMT type 1A (MIM 118220)
(McKusick 1992), the most common, accounts for
170% of CMT cases. A 1.5-Mb DNA duplication of
chromosome 17p11.2-p12 is observed in most patients
with CMT type 1A. A gene-dosage effect resulting in
abnormal expression of the PMP22 gene, which encodes
a myelin protein of the peripheral nerves, has been im-
plicated in this disorder (Lupski 1992). In support, point
mutations in the PMP22 gene have been observed in
patients with CMT type 1A who do not have the 1.5-
Mb duplication (Roa et al. 1993c; Navon et al. 1996;
Nelis and van Broeckhoven 1996; Marrosu et al. 1997).
CMT type 1B (MIM 118200) is associated with point
mutations in the myelin protein zero gene (MPZ, P0)
on chromosome 1q.
CMT with deafness is unusual and has been reported
in autosomal dominant (MIM 118300) families. In the
family reported by De Weerdt and Heerspink (1974),
hearing loss began in individuals at age ∼30–40
years and was slowly progressive. Boltshauser et al.
(1989) described hereditary motor-sensory neuropathy
(HMSN), vocal cord paralysis, and progressive senso-
rineural hearing loss in three individuals in a three-gen-
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eration family. One study (Gadoth et al. 1991), involving
16 patients from five families, documented autosomal
dominant HMSN type I in three isolated individuals
with a history of hearing impairment and showed sen-
sorineural hearing loss in five of seven patients who un-
derwent audiometry.
Linkage studies were performed with one family from
Israel exhibiting CMT and sensorineural deafness, fea-
tures of which were apparent in early childhood and
infancy (Hamiel et al. 1993). Duplication of the
17p11.2-p12 locus commonly associated with CMT
type 1A was not observed, and linkage to this locus was
excluded by the use of molecularmarkersmappedwithin
this region. CMT type 1B was also excluded through
phenotyping of the Duffy blood group linked to chro-
mosome 1q21-q23. Molecular studies were not per-
formed in earlier reports of autosomal dominant deaf-
ness and motor-sensory neuropathy. An X-linked
motor-sensory neuropathy with deafness and mental re-
tardation (MIM 310490) was found to link to Xq24-
26 (Cowchock et al. 1985; Priest et al. 1995). Autosomal
recessive CMT and deafness (MIM 214370) was also
reported in three sons of first-cousin parents (Cornell et
al. 1984). Kalaydjieva et al. (1996) reported linkage to
chromosome 8q24 in a Gypsy community from Bulgaria
with autosomal recessive HMSN, deafness, and unusual
neuropathological features (MIM 601455).
Rapid progress has been made in the identification of
genes associated with deafness. To date,20 autosomal
dominant and 25 autosomal recessive forms of nonsyn-
dromic deafness have been mapped, and 15 of the rel-
evant genes have been cloned (Hereditary Hearing Loss
home page). Two autosomal dominant deafness loci col-
ocalize with CMT. CMT type 1B and deafness locus
DFNA7 (Fagerheim et al. 1996) both map to 1q21-q23.
DFNA12 (Verhoeven et al. 1997; Kirschofer et al. 1998)
colocalizes with CMT type 4B on chromosome 11q22-
q24. The corresponding deafness genes for these loci are
unknown. The deafness locus DFNB3 was mapped to
chromosome 17p11.2-p12 in families from Bengkala,
Bali, with autosomal recessive deafness (Friedman et al.
1995). Subsequently, mutations in the myosin gene
MYO15 have been observed in affected individuals in
three unrelated families in Bali (Wang et al. 1998).
Our study involves a large central Illinois family with
autosomal dominant CMT and deafness, originally re-
ported by Kousseff et al. (1982). Most early reports did
not evaluate CMT in association with hearing loss mo-
lecularly or cytogenetically. The single linkage study of
autosomal dominant CMT and deafness excluded both
the CMT type 1A and type 1B loci. Because of these
earlier studies, our hypothesis was that a unique gene
was responsible for deafness with the CMT phenotype.
Subjects, Material, and Methods
Ascertainment of Family Members
Members of a seven-generation central Illinois family,
segregating for CMT with deafness, were included in the
present study (fig. 1). Informed consent was provided
by all participants prior to their inclusion in the study.
Individuals received a neurological examination in ad-
dition to comprehensive audiological and nerve-con-
duction studies to establish affection status. Affected in-
dividuals have degeneration of peripheral nerves
resulting in distal muscle atrophy, sensory loss, loss of
reflexes, and deformities of hands and feet.Most affected
adult individuals report sensorineural deafness.
To evaluate for the CMT type 1A duplication, cyto-
genetic and molecular analyses were performed by com-
mercial laboratories. Athena Diagnostics performed re-
striction endonuclease digestion and Southern blot
analysis of pulse-field electrophoresed genomic DNA
from one affected individual (pedigree identity V:30).
SacII-digested DNA was hybridized with a CMT type
1A repeat-element probe to visualize disease-specific
junction fragments (Lorenzetti et al. 1995). FISH anal-
ysis of interphase nuclei with cosmid contigs spanning
the PMP22 locus was also performed on affected indi-
vidual V:30 (Kleberg Cytogenetics Laboratory; Shaffer
et al. 1997).
Audiological Assessment
Family members had a comprehensive audiological
test battery, including pure-tone air and bone conduction
thresholds, speech reception thresholds, word recogni-
tion, tympanometry, acoustic reflex measures, auditory
brain stem response testing, middle latency responses,
spontaneous otoacoustic emissions, transient otoacous-
tic emissions, and distortion product otoacoustic emis-
sions.
DNA-Marker Analysis
Peripheral venous blood was obtained by standard
venipuncture. Genomic DNA was extracted by means
of the Genomix DNA extraction kit (TEL-TEST). In
cases where blood samples could not be obtained, buccal
scrapings were collected and processed with standard
methods. An initial genome scan was performed with
microsatellite markers (Research Genetics) to exclude or
include linkage to known chromosome locations of sev-
eral types of CMT: D17S1843 (CMT type 1A, 17p11.2-
p12), D1S2635 and CRP (CMT type 1B, 1q21-q23),
D12S342 (CMT type 2, 12q24), D1S199 and D1S228
(CMT type 2A, 1p35-36), D3S1551 (CMT type 2B,
3q13-q20), D8S551 (CMT type 4A, 8q13-q21.1), and
D11S900 (CMT type 4B, 11q23). A maximum LOD

Figure 1 Pedigree of family affected with autosomal dominant CMT and deafness showing haplotype analysis for 15 markers on 17p11.2. Markers are listed top to bottom: telomere-D1S921-
D17S839-D17S1357-CMT-D17S122-D17S261-D17S1857-D17S953-D17S1843-D17S740-D17S71-D17S2207-D17S2201-D17S842-D17S959-D17S783-centromere. For each marker, the alleles were
numbered on the basis of sizes reported in the Genome Database. Novel alleles were assigned numbers after the last reported allele in the Genome Database. The site of the CMT1A/PMP22 gene
locus is included in relation to its position to the molecular markers. A plus sign () designates the disease allele; a minus sign (), the nondisease allele. The boldfaced bars represent the disease
haplotype linked to CMT with deafness. Circles denote females, squares denote males, slashed symbol denotes deceased individuals, blackened symbol denotes affected individuals. An arrow indicates
the proband.
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score of 6.31, with marker D17S1843 at recombination
fraction (v)  .03, indicated linkage to chromosome
17p11.2-p12. Linkage refinement was conducted with
additional chromosome 17 markers: D17S921,
D17S839, D17S1357, D17S122, D17S261, D17S1857,
D17S953, D17S1843, D17S740, D17S71, D17S2201,
D17S842, D17S959, and D17S783. Marker D17S2207,
a highly polymorphic (CA)n microsatellite repeat located
upstream of the DFNB3/MYO15 gene, was used to an-
alyze linkage to this deafness locus (kindly provided by
Dr. Thomas B. Friedman, National Institute on Deafness
and Other Communication Disorders [NIDCD]). Am-
plification was performed with forward primers tagged
with fluorescent dyes, as provided by manufacturer.
Primers not provided in the tagged form were end-la-
beled with fluoroscein with the 5′-oligolabelling for flu-
orescence kit (Amersham Pharmacia Biotech). Amplifi-
cation products were analyzed on a 6% denaturing
polyacrylamide gel and visualized with an FMBIO-100
fluorescent image scanning unit (Hitachi). A PowerPlex
allelic ladder (Promega) was loaded onto each gel to
permit sizing of individual alleles. Alleles were scored,
and genotype data were entered into the pedigree file of
the LINKAGE computer package.
Linkage Analysis
A standard LOD-score approach for linkage analysis
was used with the software LINKAGE, for the two-point
analyses, and with the VITESSE program, for multipoint
analysis (O’Connell and Weeks 1995). To allow for chil-
dren who have not yet shown any clinical evidence of
CMT, age-dependent penetrance was taken into account
in the genetic model of autosomal dominant disease. The
four dependent risk classes identified were I: 0–6 years
old, .176; II: 7–20 years old, .588; III: 21–31 years old,
.893; and IV: 32 years, .999. The genetic maps of the
markers and allele frequencies were taken from the Ge-
nome Database. When allele frequency information was
unavailable, the allele frequency was obtained from ped-
igree data.
Mutation Analysis of PMP22
We amplified the four coding exons of PMP22
from genomic DNA of affected and unaffected individ-
uals, using exon-specific primer pairs (Roa et al. 1993c).
The two noncoding exons were amplified with designed
primers based on the published sequences (Suter et al.
1994). These primers were as follows: exon 1A forward
primer sequence: 5′-CCAGTGGGACCTCTTGGCTA-
3′; exon 1A reverse primer: 5′-GCACAGTTTGCCAA-
TAAAAC-3′; exon 1B forward primer: 5′-GGCATCCG-
CTGAGCTACATT-3′; and exon 1B reverse primer: 5′-
CCATCTCCTTCACTCTCCCC-3′. PCR reactions con-
sisted of 200 ng genomic DNA and 0.8 mM appropriate
primers. PCR conditions were as described by Roa et al.
(1993c). All amplifications were done at an annealing
temperature of 60C, except amplification of exon 2, in
which an annealing temperature of 55C was used. The
PCR products were purified from a 3% agarose gel
(NuSieve 3:1; FMC Bioproducts) prior to analysis.
For sequence analysis, 1/20th of the initial PCR sam-
ple (gel-purified) was subjected to a second-round PCR
as described, for 25 cycles. These products were purified
from agarose, and ∼100 ngwere used in cycle sequencing
reactions according to manufacturer’s protocol (Big Dye
Terminator Cycle Sequencing; PE Applied Biosystems).
Both sense and antisense strands were sequenced. After
thermocycling, the reactions were precipitated with eth-
anol, lyophilized, and sent off to a sequencing facility
for heterozygosity analysis (ACGT).
ForHaeIII restriction-fragment–length polymorphism
(RFLP) analysis, exon 4 (coding exon 3) was amplified
from genomic DNA of family members and spouses, as
well as from 52 unrelated individuals. Each PCR reac-
tion was precipitated with ethanol in the presence of
yeast tRNA (0.5 mg) as carrier nucleic acid. The samples
were washed with 70% ethanol, lyophilized, and resus-
pended in 5 ml deionized water. Each sample was di-
gested for 16 h with 5 U HaeIII (New England BioLabs)
in a 10-ml final volume of 1 # reaction buffer, supplied
by the manufacturer. The complete reactions were an-
alyzed on a 3%NuSieve 3:1 (FMC BioProducts) agarose
gel containing 0.25 mg/ml ethidium bromide.
Results
Clinical, Electrophysiological, and Pathological Studies
Members of the family studied included 31 affected
individuals, 28 unaffected individuals, and 11 spouses.
The proband (VII:4) for this study was given a diagnosis
at birth of bilateral vocal cord palsy, swallowing inco-
ordination, and hypotonia. The respiratory distress was
managed with tracheostomy at birth, and the swallow-
ing incoordination was managed by gastrostomy tube
placement at age 3 wk. She had decreased tendon re-
flexes. Her brain stem auditory-evoked responses were
abnormal, although otoacoustic responses were normal,
indicating normal outer hair cells function. Nerve-con-
duction studies indicated slow conduction velocities. At
age 18 mo she died from respiratory compromise. Her
mother (VI:8) reported having had, in her teens, muscle
weakness that caused difficulty in walking, husky soft
voice, and hearing loss, and her maternal grandfather
had developed mild features of CMT in his twenties. In
addition to the proband, another male infant (VI:31)
died at age 3 mo, fromweakness, hypotonia, and feeding
difficulties. A diagnosis was not established at autopsy
to explain his death. Linkage and mutation analysis,
Kovach et al.: CMT and Deafness 1585
with autopsy material from histological analysis, indi-
cated that he had inherited his mother’s disease allele.
From the clinical data accumulated, increasing clinical
severity and younger age at onset of the neurological
features and deafness with each progressive generation
was indicated, which is indicative of anticipation. The
mean age at onset of symptoms of CMT in different
generations was 12, 9.3, 3.8, and 4.4 years for gener-
ations IV, V, VI, and VII, respectively (fig. 1). Although
the difference was not statistically significant for the en-
tire family (P .09), when each generationwas analyzed
separately for each individual branch of the family, there
was evidence of earlier age at onset (P  .009). The
mean ages reported for onset of deafness in the three
generations—generations IV, V, and VI—were 41, 18.4,
and 12.9 years, respectively. The age difference in each
generation was statistically significant (P  .004). Deaf-
ness and features of CMT are progressive in this family.
Because many individuals in the youngest generation do
not have documented deafness and are too young to
cooperate with the comprehensive audiology research
studies, generation VII was not included in the latter
analysis.
All affected individuals have had routine audiology
studies. Nineteen affected and eight unaffected family
members have had comprehensive audiological assess-
ments. The details are described in a separatemanuscript
(K. Campbell, L. Hughes, L. Mazzeo, M. Kovach, V.
Kimonis, unpublished data). The sensorineural hearing
losses in the affected family members ranged from bor-
derline normal to profound hearing loss, with all having
at least mild bilateral hearing loss by adulthood. Word
recognition was often poorer than would be predicted
from pure-tone thresholds, which is consistent with au-
ditory neuropathy.
A variety of abnormalities consistent with peripheral
auditory neuropathy were noted on the auditory elec-
trophysiological test battery for all affected family mem-
bers. More than half the affected family members had
a clearly replicable cochlear microphonic, with almost
half of those showing a marked enlargement. The coch-
lear microphonic, which emanates from the AC electric
activity of the cochlear outer hair cells, has been reported
to be markedly enlarged in some cases of auditory neu-
ropathy, and this enlargement may be pathognomonic
to that disorder.
The auditory brain stem response (ABR), measuring
auditory electric responses from the VIIIth nerve through
the lateral lemniscus, was abnormal in all affected pa-
tients, which is consistent with otoneurological abnor-
mality. The most common abnormality was delayed
waveform latencies. In the remainder of the affected pa-
tients, all ABR waveforms were absent. Middle latency
responses, measured through the auditory thalamocort-
ical area, were less commonly affected but still were
either absent or of poor morphology in 150% of the
affected patients.
Acoustic reflex abnormalities were also present. These
abnormalities included elevated acoustic reflex thresh-
olds, absent acoustic reflexes, or acoustic reflex decay.
Acoustic reflex studies were normal in only one affected
patient.
The results of the otoacoustic emissions testing, sen-
sitive measures specifically of cochlear function, also
yielded consistently abnormal results, clearly suggesting
cochlear involvement as well. Audiological studies of
patients with CMT disease and deafness have suggested
that the hearing impairment may be entirely neural (Ga-
doth et al. 1991), but in the family reported in the pre-
sent study, a concomitant cochlear component is present.
The patients report that their hearing losses are pro-
gressive, but longitudinal studies have not yet been
performed.
Nerve-conduction velocities are slow (mean motor
and sensory 24 m/s), suggestive of CMT type 1A. Elec-
tron microscopy of a sural nerve obtained from the
mother of the proband revealed “onion bulb” whorls
composed of multiple Schwann-cell lamellae surround-
ing demyelinated or thinly myelinated axons. Results of
electron microscopy of muscle were normal.
Molecular and Cytogenetic Analysis for CMT Type 1A
Duplication
Pulsed-field gel electrophoresis and Southern blot
analysis performed on affected individual V:30 did not
detect the 500-kb junction fragment diagnostic of the
CMT type 1A common duplication. The absence of the
duplication at 17p11.2-12 was confirmed by FISH anal-
ysis of interphase nuclei from the same individual and
by PCR assay with polymorphic microsatellite marker
D17S1357 (Blair et al. 1995).
Linkage Analysis
CMT types 1B, 2, 2A, 2B, 4A, and 4B were excluded
by LOD scores of 2.00. A maximum LOD score
(Zmax) of 6.31 at v .10 for marker D17S1843 indicated
linkage to the CMT type 1A locus on chromosome
17p11.2-p12. To ascertain whether there was cosegre-
gation with the deafness locus DFNB3, a high-density
map of this region was obtained by genotyping of in-
dividuals with additional closely spaced markers that
spanned the genetic interval between D17S921 and
D17S783. A Zmax of 9.01 was obtained for D17S1357
at v  .03. Multipoint LOD score analysis gave a Zmax
of 11.1.
Haplotype Analysis
To determine whether the smallest interval containing
the CMTwith deafness locus included theMYO15 gene,
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Figure 2 Genetic map of chromosome 17p11.2 markers. The
sites for the autosomal recessive deafness (DFNB3) locus and CMT
type 1A duplication region are indicated. The CMT and deafness crit-
ical region, defined by markers D17S839 and D17S122, is represented
by a boldfaced bar. Genetic distances and placement of PMP22 were
obtained from PAC/BAC map of the CMT type 1A duplication region
(personal communication, Dr. J. R. Lupski).
we analyzed individuals for recombination events by us-
ing haplotype reconstruction (fig. 1). The cosegregating
segment in which no recombination was detected was
flanked by the markers D17S839 and D17S122.
Figure 2 summarizes the conclusions derived from
haplotype analysis. The critical region defined by mark-
ers D17S839 and D17S122 spans ∼0.6 Mb of 17p11.2
(a detailed map of 17p11.2-p12 duplication region was
kindly provided by Dr. J. R. Lupski). The only marker
for which recombinations have not been observed is
D17S1357. This marker is within the same bin as
PMP22 and has been used to detect the CMT type 1A
duplication (Blair et al. 1995), highly suggestive of
PMP22, representing the candidate gene for this disor-
der. The MYO15 gene has been excluded as a result of
recombinations observed.
Mutation Analysis
Mutation analysis was performed to determine
whether affected individuals in this family carried mu-
tations in PMP22, because CMT with deafness maps to
chromosome 17p11.2-p12, the CMT type 1A locus, and
affected individuals do not carry the common 1.5-Mb
duplication associated with 70% of CMT type 1A cases.
Heteroduplex analysis (Roa et al. 1993c) did not detect
mutations in the PMP22 gene. Sequence analysis of all
coding and noncoding exons was also performed on one
unaffected individual and three affected individuals.
Both strands of the generated PCR products were se-
quenced. A GrC transversion was detected at position
248 in exon 4 (coding exon 3) in the heterozygous state
(fig. 3A). This mutation is predicted to result in a single
amino acid substitution of proline for alanine at codon
67. Mutations were not detected in any other exon.
The GrC point mutation results in the loss of a cleav-
age site for restriction enzymes HaeIII and BstNI. All
individuals in the pedigree were subjected to RFLP anal-
ysis of exon 4 with HaeIII (fig. 3B). Digestion with
HaeIII produced two fragments of 159 and 55 bp in all
unaffected individuals. Individual VI:9 is only 8 years
old, however, and thus far exhibits no clinical features
of CMT. She shares the disease haplotype for markers
D17S71, D17S2207, D17S2201, D17S842, D17S959,
and D17S783 but did not inherit the critical region of
linkage. RFLP analysis with HaeIII indicated that she
was unaffected. The RFLP pattern in affected individuals
reflected the heterozygous state, generating three prod-
ucts 214, 159, and 55 bp in length. This mutation was
not observed in spouses of family members or in 52
unrelated controls.
Discussion
CMT is rarely associated with deafness but is observed
sporadically in patients with peripheral neuropathies. A
large family exhibiting autosomal dominant CMT and
deafness provided a unique opportunity for molecular
analysis of this distinct disorder. Linkage studies of CMT
and deafness in the family reported by Hamiel et al.
(1993) excluded CMT types 1A and 1B loci. Our find-
ings indicate linkage to CMT type 1A chromosomal lo-
cus 17p11.2-p12. Two candidate genes, MYO15 of the
DFNB3 locus and PMP22 of the CMT type 1A locus,
map to this region. Homozygous mutation in MYO15,
which encodes an unconventional myosin, leads to au-
tosomal recessive nonsyndromic deafness (Friedman et
al. 1995; Wang et al. 1998). Because dominant and re-
cessive forms of deafness can be caused by genetically
distinct mutations within the same gene (Tamagawa et
al. 1996; Weil et al. 1997), MYO15 was evaluated as a
possible candidate gene with high-density marker and
haplotype analysis. Recombinations with the disease lo-
cus and genetic markers telomeric of D17S122, however,
excluded the DFNB3 locus (fig. 1 and 2).
A search of the Human Cochlear EST Database re-
veals that PMP22 is presently the only known gene ex-
pressed in the cochlea that maps to position 17p11.2-
p12. It is a 160–amino acid–membrane glycoprotein
highly expressed by Schwann cells in compact myelin of
the peripheral nervous system (Snipes et al. 1992). Du-
plication of PMP22 and, occasionally, point mutations
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Figure 3 A, Identification of the GrC mutation in PMP22 exon 4. The sense and antisense sequences are shown for an unaffected (V:
7) and an affected (VI:19) family member. An arrow indicates the location of the GrC heterozygous point mutation. Note that the automatic
sequence generated miscalled the mutated nucleotide in the sense strand, but the peak height has changed in the affected individual. B,
Confirmation of GrC heterozygous point mutation by RFLP analysis. This point mutation results in the loss of a restriction cut site for enzyme
HaeIII. Digestion of genomic DNA from the unaffected individual (V:7) produced two fragments of 159 and 55 bp. RFLP analysis of the
affected individual (VI:19) generated three fragments of 214, 159, and 55 bp, representing the heterozygous state of mutation. The 55-bp
restriction fragment is not shown in this gel.
within the gene have been implicated in the cause of
CMT type 1A. It has been proposed that abnormal ex-
pression (a gene-dosage effect due to the duplication)
and altered protein structure of PMP22 results in im-
paired function of peripheral myelin in patients with
CMT (Lupski 1992; Snipes et al. 1992). Sequence anal-
ysis of PMP22 revealed a unique dominant missense
mutation that cosegregates with deafness and CMT in
the family studied.
Table 1 presents known mutations in PMP22. In-
cluding the mutation in this report, 24 autosomal
dominant mutations are known. Of the 19 missense mu-
tations, 14 are the result of nonconservative substitu-
tions. With the exception of Gly93Arg, which is located
in the intracellular loop between transmembranedomain
2 (TM2) and TM3 (fig. 4), all the amino acid changes
occur within the transmembrane domains. Point mu-
tations in PMP22 are commonly associated with Dejer-
ine-Sottas syndrome (DSS; MIM 145900), a clinically
more severe neuropathy than CMT. Those affected with
DSS typically have nerve-conduction velocities !10 m/s
and have an earlier age at onset than that of patients
with CMT type 1A duplication (Roa et al. 1993a; Val-
entijn et al. 1995). Classic CMT has also been reported
to be caused by point mutations in PMP22. There does
not appear to be a defined category of PMP22 point
mutations that can distinguish between CMT and DSS;
therefore, DSS and CMT represent a spectrum of related
disorders.
Mutations responsible for the clinically reported
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Table 1
PMP22 Point Mutations
Clinical Description and Mutation Residue Reference
DSS:
TrA transversion Met69Lys Roa et al. 1993a
GrT transversion Gly150Cys Ikegami et al. 1998
GrA transition Gly150Asp Ionasescu et al. 1997
GrA transition Gly100Glu Marques et al. 1998
GrA transition Gly100Arg Bort et al. 1997
TrC transition Ser79Pro Bort et al. 1998
CrA transversion His12Gln Valentijn et al. 1995
CrG transversion Ser72Trp Tyson et al. 1997
TrC transition Leu80Pro Tyson et al. 1997
2-bp insertion Shift at Leu80 Ikegami et al. 1998
CrT transition Ser72Leu Roa et al. 1993a
CrT transition Ser72Leu Ionasescu et al. 1995
CrT transition Ser72Leu Marques et al. 1998
DSS and hearing loss:
CrT transition Ser72Leu Ionasescu et al. 1996
GrT transversion Ser76Ile Tyson et al. 1997
CMT type 1A and hearing loss:
GrC transversion Ala67Pro Present study
CMT type 1A:
CrG transversion Ser79Cys Roa et al. 1993b
TrG transversion Leu147Arg Navon et al. 1996
IVS31, splice site TGgtrTGat Nelis and van Broekhoven 1996
TrC transition Leu16Pro Valentijn et al. 1992
GrT transversion Gly107Val Marrosu et al. 1997
GrC transversion Gly93Arg Ohnishi et al. 1995
CMT type 1A, recessive:
CrT transition Thr118Met Roa et al. 1993b
HNPP:
2-bp deletion Stop at Ser41 Nicholson et al. 1994
1-bp deletion Stop at Val154 Taroni et al. 1995
IVS11, splice site GCgtrGCtt Bort et al. 1997
1-bp deletion Shift at Arg95 Young et al. 1997
GrA transition Val30Met Sahenk et al. 1998
Trembler mouse mutants:
Trembler Gly150Asp Suter et al. 1992b
Trembler-J Leu16Pro Suter et al. 1992a
CMT/DSS cases are dispersed throughout all four trans-
membrane domains and one intracellular domain. In-
dividual missense mutations at codon 79 resulted in two
distinct clinical phenotypes: Ser79Cys manifested as
CMT (Roa et al. 1993c) and Ser79Pro manifested as
DSS (Bort et al. 1998). The structural/biochemical na-
ture of the substituted residue may influence the phe-
notype; however, it is not unusual for the CMT phe-
notype to vary, as observed even among members of the
same family who carry identical mutations.
Although PMP22 involvement in deafness has not
been addressed, two isolated cases of de novo DSS and
hearing loss have been reported (Ionasescu et al. 1996;
Tyson et al. 1997). Both of these mutations occur within
the second transmembrane domain of PMP22 (fig. 4)
and result in polar to nonpolar amino acid substitutions
for codons 72 and 76, respectively. Ser72 appears to be
a mutational hotspot, with Ser72Leu mutations being
reported in three de novo cases of DSS with severe clin-
ical features without deafness (Roa et al. 1993a; Iona-
sescu et al. 1995; Marques et al. 1998) and a single de
novo case of DSS associated with deafness (Ionasescu et
al. 1996). The latter patient was a significantly devel-
opmentally delayed 32-year-old woman who was wheel-
chair bound. She had facial weakness, nystagmus, and
scoliosis, which required surgery. Her nerve-conduction
velocity was 11 m/s. The patient was heterozygous for
the mutation, suggestive of a dominant allele, and did
not carry the common CMT type 1A duplication. None
of the other three patients associated with the Ser72Leu
mutation had reported deafness. Details of her senso-
rineural hearing loss, which the authors speculated could
have been acquired, were not available from the report.
An isolated case reported by Tyson et al. (1997), asso-
ciated with the Ser76Ile exchange in TM2, was that of
a 39-year-old woman whose hearing was impaired for
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Figure 4 Proposed protein structure of PMP22 (figure adopted
from Roa et al. 1993a). PMP22 is predicted to have four transmem-
brane domains (TM1–TM4) and oneN-glycosylation site (N41) (Suter
et al. 1992a). A b-sheet conformation is predicted for domains TM1,
2, and 4, whereas TM3 is thought to be a-helical in nature. The 160
amino acids of PMP22 are represented in single-letter code. Substi-
tutions because of single-base point mutations are shaded, with an
arrow pointing to the designation of the changed residue. The unique
substitution associated with CMT and deafness (Ala67Pro) reported
in this paper is represented by an asterisk (∗). Point mutationsobserved
in patients given a clinical diagnosis of CMT are double encircled.
Circles wrapped by a square designate the two mutations in which
deafness was reported elsewhere, in addition to CMT.Mutations iden-
tical to the trembler (Gly150Asp) and trembler-J (Leu16Pro) mouse
genotypes are indicated by a diamond (). Multiple substitutions have
been reported for three residues (Ser72, Ser79, and Gly100).
10 years, but details of audiological testing were not
available from the report. Deafness was not reported in
the other cases associated with mutations in PMP22.
We report a unique missense mutation in PMP22 re-
sulting in an amino acid exchange (Ala67Pro), also in
TM2. This mutation is associated with CMT and deaf-
ness, an unusual phenotype. Proline is a structurally
rigid, rarely used amino acid that causes sharp bends in
peptide chains and most likely destabilizes the predicted
b-sheet conformation of TM2. It has been speculated
that PMP22 acts as a pore or channel protein (Suter et
al. 1992a) or is involved in interactions between axons
and Schwann cells (Snipes et al. 1993). The proximity
of the destabilizing proline substitution to the extracel-
lular domain could significantly affect extracellular in-
teractions of PMP22 with itself or other molecules, as
well as interfere with proper integration into the myelin
membranes.
The basis of hearing loss in this family is intriguing.
In light of the high levels of PMP22 transcript detected
in the cochlea (Robertson et al. 1994), a relationship
between deafness and the unique PMP22 mutation ob-
served in this family is an attractive theory. Examination
of PMP22 involvement in myelination and nerve con-
duction in this tissue should prove interesting. In the
auditory system, the VIIIth nerve, surrounded by
Schwann cells, would be the most likely site of auditory
neuropathy for this family. The prolongation of ABR
interpeak latencies and/or absence of ABR waveforms
would generally be consistent with this putative site of
lesion.
VIIIth-nerve abnormalities should most notably pro-
long the I–III interpeak interval of the ABR or cause
absence of earlier waveforms with only a delayed wave
V present. These findings were typical in this family.
However, some individuals also showed III–V prolon-
gations, suggesting involvement of the central auditory
pathways. Although PMP22 mutations may primarily
affect the periphery, PMP22 mRNA has been found in
the central nervous system, particularly during devel-
opment (Parmantier et al 1995). Central auditory path-
ways are myelinated from the brain stem through cor-
tical levels, although PMP22 expression specifically in
those pathways has not yet been investigated.
The mechanisms of cochlear involvement in this fam-
ily, as reflected in otoacoustic emission abnormalities,
are not well defined. Whereas PMP22 is abundantly ex-
pressed by Schwann cells of the peripheral nervous sys-
tem, comparatively lower levels of PMP22 transcripts
have also been detected in nonneural cell types (Welcher
et al. 1991), where their expression is regulated in a
growth-specific manner. Therefore, PMP22 might have
a hitherto unknown role in regulation of cell growth and
cell-to-cell interactions and, consequently, cochlear
development.
Unlike CMT associated with the PMP22 duplication
and a gene-dosage effect, the Ala67Pro mutation is likely
to cause a dominant-negative effect, like the majority of
DSS and CMT point mutations. Because these other
PMP22 allele variant mutations are not associated with
an obvious gross impairment of hearing, the phenotypic
differences seen with the Ala67Pro mutation probably
indicate either a codon-specific effect or a genetic back-
ground effect.
Codon-specific effects are well described for other
pore or channel proteins, including several that are im-
portant in hearing (Kelsell et al. 1997; Xia et al. 1998).
The X-linked form of CMT (CMTX), caused by mu-
tations in connexin 32 (GJB1) (Bergoffen et al. 1993),
is sometimes coupled with mild deafness (Nicholson and
Corbett 1996). Although the pathophysiogical basis for
hearing loss in CMTX has not been studied at the mo-
lecular level, mutations in two other gap junction pro-
teins, connexin 26 (GJB2) (Kelsell et al. 1997) and con-
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nexin 31 (GJB3) (Xia et al. 1998), are associated with
hearing loss. Connexin 26 transcripts have been isolated
from the cochlea, and expression of the connexin 31 has
been identified in inner ear tissue (Xia et al. 1998). Be-
cause GJB1 can form heterotypic channels with GJB2
(White et al. 1995), the finding of mild deafness with
some forms of CMTX is not surprising. The protein
structure of PMP22 bears a close resemblance to con-
nexins, is also expressed cochlearly, and could play a
role in cochlear function similar to that speculated for
connexins in CMTX with deafness.
Clinical data for this family are suggestive of antici-
pation. An increased severity and younger age at onset
of the neurological features and deafness have been ob-
served with each progressive generation. Two affected
individuals aged !2 years died from severe manifestation
of CMT. Trinucleotide-repeat expansion is often asso-
ciated with anticipation in neurodegenerative disorders.
The majority of these genetic diseases are characterized
by enlargement of the normally polymorphic CAG/CTG
or CGG/CCG repeats (Ashley and Warren 1995). Fried-
reich’s ataxia is a trinucleotide-repeat–expansion dis-
order distinguished by an intronic GAA triplet repeat
expansion (Campuzano et al. 1996).
A correlation between disease severity and triplet re-
peat length was not observed in this family (data not
shown). Although generational expansion was not de-
tected in either maternal or paternal modes of trans-
mission, the Repeat Expansion Detection (RED) assay
used (Schalling et al. 1993) is a genomewide search of
triplet repeat expansions, and small-scale expansions
could potentially be masked by the normal level of triplet
repeat lengths present within the genome of an
individual.
This is the first report of a stable, dominant, unique
mutation in PMP22 causing deafness in addition to
CMT. The phenotypic variability and anticipation of
CMT in this family are difficult to explain by a single
gene mutation, but this has been reported in other dis-
orders (Peral et al. 1996; Fraser 1997). Marrosu et al.
(1997) also noted an inconsistent genotype-phenotype
correlation and an anticipation-like phenomenon in a
five-generation family with CMT type 1A resulting from
a PMP22 point mutation. It could be speculated that
additional factors, such as another locus, a unique mu-
tation such as a trinucleotide-repeat expansion, genetic
background, and environmental influences contribute to
this unusual disease manifestation.
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